Moderna Inc. saw its stock price climb sharply on Tuesday, closing at $39.60 per share after a 17.02 percent gain. The surge followed the company's presentation at the 44th Annual JP Morgan Healthcare Conference on Monday, where it provided preliminary financial figures for the coming years.
For the full year 2025, Moderna expects to report revenues of $1.9 billion. This figure exceeds the midpoint of the $1.6 billion to $2 billion guidance range previously communicated during its third quarter earnings call.
CEO Stephane Bancel stated, "In 2025, we strengthened our commercial execution, successfully launched our third product, and continued to advance our mRNA pipeline. At the same time, we reduced our annual operating expenses by approximately $2 billion, significantly exceeding the financial cost reduction commitments we set at the start of the year."
Looking ahead to 2026, the company reaffirmed plans to deliver up to 10 percent revenue growth. It also aims to further lower operating expenses to a range of $4.2 billion to $4.6 billion, targeting a break-even point by 2028.
Bancel added, "We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations, creating a strong cash engine to fund our next phase of innovation in oncology and rare disease. We expect this approach to support up to 10 percent revenue growth in 2026, as we further reduce costs, expand our commercial portfolio with approvals of additional seasonal vaccines, and anticipate multiple clinical data catalysts driven by our late-stage oncology pipeline."
Official financial results are scheduled for release in the second week of next month.